| Literature DB >> 36031599 |
Bob Kiaii1, Stephen S Johnston2, Se Ryeong Jang3, Nivesh Elangovanraaj4, Pranjal Tewari4, Brian Po-Han Chen3.
Abstract
BACKGROUND: To compare clinical and economic outcomes after sternotomy for cardiac surgery with skin closure through 2-octyl cyanoacrylate plus polymer mesh tape (2OPMT) versus conventional absorbable sutures plus waterproof wound dressings (CSWWD).Entities:
Keywords: 2-octyl cyanoacrylate; Absorbable sutures; Skin closure; Sternotomy
Mesh:
Substances:
Year: 2022 PMID: 36031599 PMCID: PMC9420285 DOI: 10.1186/s13019-022-01956-x
Source DB: PubMed Journal: J Cardiothorac Surg ISSN: 1749-8090 Impact factor: 1.522
Fig. 1Graphical abstract
Fig. 2Absolute standardized mean differences for matching variables before and after propensity score matching. *A standardized mean difference with an absolute value ≤ 0.10 is considered to balanced
Patient demographic characteristics of study groups after propensity score matching
| 2OPMT group | CSWWD group | Std. Diff.* | |||
|---|---|---|---|---|---|
| N | 5,338 | 100% | 5,338 | 100% | |
| Age, mean/SD | 65 | 10.68 | 65 | 10.53 | 0.000 |
| Age category, N/% | |||||
| 18–34 | 51 | 1.00% | 52 | 1.00% | −0.002 |
| 35–44 | 147 | 2.80% | 142 | 2.70% | 0.006 |
| 45–54 | 548 | 10.30% | 548 | 10.30% | 0.000 |
| 55–64 | 1,416 | 26.50% | 1,452 | 27.20% | −0.015 |
| 65–74 | 2,062 | 38.60% | 2,082 | 39.00% | −0.008 |
| 75–84 | 1,024 | 19.20% | 986 | 18.50% | 0.018 |
| 85+ | 90 | 1.70% | 76 | 1.40% | 0.021 |
| Female, N/% | 1,487 | 27.90% | 1,499 | 28.10% | −0.005 |
| Marital status, N/% | |||||
| Married | 3,230 | 60.50% | 3,201 | 60.00% | 0.011 |
| Single | 1,864 | 34.90% | 1,877 | 35.20% | −0.005 |
| Other | 229 | 4.30% | 249 | 4.70% | −0.018 |
| Unknown | 15 | 0.30% | 11 | 0.20% | 0.015 |
| Race, N/% | |||||
| Black | 401 | 7.50% | 419 | 7.80% | −0.013 |
| Asian | 86 | 1.60% | 79 | 1.50% | 0.011 |
| White | 4,554 | 85.30% | 4,500 | 84.30% | 0.028 |
| Other | 239 | 4.50% | 273 | 5.10% | −0.030 |
| Unknown | 58 | 1.10% | 67 | 1.30% | −0.016 |
| Payer, N/% | |||||
| Commercial | 1,393 | 26.10% | 1,392 | 26.10% | 0.000 |
| Medicaid | 375 | 7.00% | 393 | 7.40% | −0.013 |
| Medicare | 3,177 | 59.50% | 3,153 | 59.10% | 0.009 |
| Other | 393 | 7.40% | 400 | 7.50% | −0.005 |
| Discharge Year, N/% | |||||
| 2015 (October onwards) | 69 | 1.30% | 72 | 1.30% | −0.005 |
| 2016 | 693 | 13.00% | 671 | 12.60% | 0.012 |
| 2017 | 1,185 | 22.20% | 1,146 | 21.50% | 0.018 |
| 2018 | 1,331 | 24.90% | 1,304 | 24.40% | 0.012 |
| 2019 | 1,469 | 27.50% | 1,503 | 28.20% | −0.014 |
| 2020 (through June) | 591 | 11.10% | 642 | 12.00% | −0.030 |
SD standard deviation; Std. Diff. standardized mean difference
*A standardized mean difference with an absolute value ≤ 0.10 is considered to balanced
Patient clinical characteristics of study groups after propensity score matching
| 2OPMT group | CSWWD group | Std. Diff.* | |||
|---|---|---|---|---|---|
| N | 5,338 | 100% | 5,338 | 100% | |
| Comorbidities, N/% | |||||
| Alcohol abuse | 183 | 3.40% | 183 | 3.40% | 0.000 |
| Cancer | 45 | 0.80% | 55 | 1.00% | 0.019 |
| Cardiac arrhythmias | 1,291 | 24.20% | 1,344 | 25.20% | −0.023 |
| Chronic pulmonary disease | 1,287 | 24.10% | 1,275 | 23.90% | 0.005 |
| Coagulopathy | 399 | 7.50% | 395 | 7.40% | 0.003 |
| Congestive heart failure | 1,813 | 34.00% | 1,821 | 34.10% | −0.003 |
| Deficiency anemia | 114 | 2.10% | 118 | 2.20% | −0.005 |
| Depression | 549 | 10.3% | 552 | 10.3% | −0.002 |
| Diabetes, complicated | 1,496 | 28.00% | 1,502 | 28.10% | −0.003 |
| Diabetes, uncomplicated | 937 | 17.60% | 933 | 17.50% | 0.002 |
| Drug abuse | 174 | 3.30% | 176 | 3.30% | −0.002 |
| Hypertension, uncomplicated | 2,675 | 50.10% | 2,676 | 50.10% | 0.000 |
| Hypertension, complicated | 2,123 | 39.80% | 2,113 | 39.60% | 0.004 |
| Hypothyroidism | 687 | 12.90% | 673 | 12.60% | 0.008 |
| Liver disease | 150 | 2.80% | 160 | 3.00% | −0.011 |
| Obesity | 1,676 | 31.40% | 1,687 | 31.60% | −0.004 |
| Neurological disorders | 162 | 3.00% | 156 | 2.90% | 0.007 |
| Paralysis | 13 | 0.20% | 11 | 0.20% | 0.008 |
| Peripheral vascular disease | 958 | 17.90% | 985 | 18.50% | −0.013 |
| Pulmonary circulation disorders | 408 | 7.60% | 418 | 7.80% | −0.007 |
| Renal failure | 1,181 | 22.10% | 1,196 | 22.40% | 0.007 |
| RA/collagen vascular diseases | 152 | 2.80% | 138 | 2.60% | 0.016 |
| Valvular disease | 1,870 | 35.00% | 1,892 | 35.40% | −0.009 |
| Weight loss | 101 | 1.90% | 108 | 2.00% | −0.009 |
| CCI, N/% | |||||
| 0 | 694 | 13.00% | 701 | 13.10% | −0.004 |
| 1–2 | 2,450 | 45.90% | 2,432 | 45.60% | 0.007 |
| 3–4 | 1,298 | 24.30% | 1,309 | 24.50% | −0.005 |
| 5+ | 896 | 16.80% | 896 | 16.80% | 0.000 |
CCI Charlson Comorbidity Index; RA rheumatoid arthritis; Std. Diff. standardized mean difference
*A standardized mean difference with an absolute value ≤ 0.10 is considered to balanced
Procedural/admission characteristics of study groups after propensity score matching
| 2OPMT group | CSWWD group | Std. Diff.* | |||
|---|---|---|---|---|---|
| N | 5,338 | 100% | 5,338 | 100% | |
| Primary diagnosis group, N/% | |||||
| Atherosclerotic heart disease of native coronary artery | 2,691 | 50.40% | 2,673 | 50.10% | 0.007 |
| Chronic disease of rheumatic origin | 196 | 3.70% | 218 | 4.10% | −0.021 |
| Non-ST elevation myocardial infarction | 1,088 | 20.40% | 1,077 | 20.20% | 0.005 |
| Nonrheumatic valve disorder | 807 | 15.10% | 812 | 15.20% | −0.003 |
| Other Circulatory Disease | 556 | 10.40% | 558 | 10.50% | −0.001 |
| Aortic procedure, N/% | 349 | 6.50% | 353 | 6.60% | −0.003 |
| Valve repair/replacement procedure, N/% | 1,333 | 25.00% | 1,379 | 25.80% | −0.020 |
| Number of bypasses, N/% | |||||
| 0 (non-CABG procedure) | 949 | 17.80% | 986 | 18.50% | −0.018 |
| 1 | 221 | 4.10% | 226 | 4.20% | −0.005 |
| 2 | 831 | 15.60% | 847 | 15.90% | −0.008 |
| 3 | 1,705 | 31.90% | 1,730 | 32.40% | −0.010 |
| 4 | 1,222 | 22.90% | 1,140 | 21.40% | 0.037 |
| 5 | 410 | 7.70% | 409 | 7.70% | 0.001 |
| Internal mammary artery bypass graft, N/% | 4,013 | 75.20% | 3,984 | 74.60% | 0.013 |
| History of cardiac surgery, N/% | 1,212 | 22.70% | 1,198 | 22.40% | 0.006 |
| Admission type, N/% | |||||
| Elective | 2,924 | 54.80% | 2,989 | 56.00% | −0.024 |
| Emergency | 1,246 | 23.30% | 1,233 | 23.10% | 0.006 |
| Information Not Available | 40 | 0.70% | 39 | 0.70% | 0.002 |
| Trauma Center | 3 | 0.10% | 2 | 0.00% | 0.009 |
| Urgent | 1,125 | 21.10% | 1,075 | 20.10% | 0.023 |
Std. Diff. standardized mean difference
*A standardized mean difference with an absolute value ≤ 0.10 is considered to balanced
Hospital/provider characteristics of study groups after propensity score matching
| 2OPMT group | CSWWD group | Std. Diff.* | |||
|---|---|---|---|---|---|
| N | 5,338 | 100% | 5,338 | 100% | |
| Urban Hospital, N/% | 5,174 | 96.90% | 5,176 | 97.00% | 0.002 |
| Teaching Hospital, N/% | 3,113 | 58.30% | 3,148 | 59.00% | 0.013 |
| Hospital Bed Size, N/% | |||||
| 0–299 | 727 | 13.60% | 733 | 13.70% | −0.003 |
| 300–499 | 1,562 | 29.30% | 1,512 | 28.30% | 0.021 |
| 500+ | 3,049 | 57.10% | 3,093 | 57.90% | −0.017 |
| Geographic region, N/% | |||||
| Midwest | 763 | 14.30% | 827 | 15.50% | −0.034 |
| Northeast | 708 | 13.30% | 662 | 12.40% | 0.026 |
| South | 3,322 | 62.20% | 3,336 | 62.50% | −0.005 |
| West | 545 | 10.20% | 513 | 9.60% | 0.020 |
| Provider annual volume, N/% | |||||
| 0–200 | 1,502 | 28.10% | 1,506 | 28.20% | −0.002 |
| 201–350 | 974 | 18.20% | 989 | 18.50% | −0.007 |
| 351–500 | 992 | 18.60% | 1,045 | 19.60% | −0.025 |
| 500+ | 1,870 | 35.00% | 1,798 | 33.70% | 0.028 |
| Procedural physician specialty, N/% | |||||
| Cardiovascular/thoracic surgery | 5,121 | 95.90% | 5,152 | 96.50% | −0.030 |
| Internal medicine | 16 | 0.30% | 13 | 0.20% | 0.011 |
| Other | 201 | 3.80% | 173 | 3.20% | 0.029 |
| Cost-to-charge ratio**, N/% | 1,384 | 25.90% | 1,353 | 25.30% | 0.013 |
SD standard deviation; Std. Diff. standardized mean difference
*A standardized mean difference with an absolute value ≤ 0.10 is considered to balanced
**Hospital costs are derived from a cost-to-charge ratio versus procedural costing
Comparison of outcomes in the propensity score matched groups
| 2OPMT group | CSWWD group | IDM (95% CI) | |||
|---|---|---|---|---|---|
| 5,338 | 5,338 | ||||
| 60-day wound complications | Adjusted effects* | ||||
| Any wound complication | % (95% CI) | 3.47% (2.82–4.12%) | 3.47% (2.81–4.13%) | 0.00% (−0.91 to 0.91%) | 0.996 |
| Mediastinitis/abscess | % (95% CI) | 0.17% (0.06–0.28%) | 0.11% (0.02–0.20%) | 0.06% (−0.09 to 0.20%) | 0.438 |
| Sternotomy dehiscence | % (95% CI) | 0.67% (0.41–0.93%) | 0.89% (0.57–1.20%) | −0.22% (−0.61 to 0.17%) | 0.277 |
| Dehiscence (site unspecified) | % (95% CI) | 1.46% (1.14–1.78%) | 1.42% (1.11–1.74%) | 0.04% (−0.42 to 0.49%) | 0.872 |
| Osteomyelitis | % (95% CI) | 0.15% (0.04–0.25%) | 0.15% (0.04–0.27%) | −0.01% (−0.17 to 0.15%) | 0.935 |
| Deep sternal wound SSI | % (95% CI) | 0.17% (0.03–0.31%) | 0.08% (0.00–0.16%) | 0.10% (−0.06 to 0.25%) | 0.212 |
| SSI (site unspecified) | % (95% CI) | 2.16% (1.70–2.62%) | 2.04% (1.59–2.48%) | 0.12% (−0.52 to 0.76%) | 0.707 |
| 60-day all-cause readmission | % (95% CI) | 12.6% (11.0–14.2%) | 13.6% (11.9–15.3%) | −1.1% (−3.3 to 1.2%) | 0.354 |
| 60-day reoperation | % (95% CI) | 10.3% (8.9–11.7%) | 10.1% (8.6–11.5%) | 0.2% (−1.7 to 2.2%) | 0.808 |
| Home discharge** | % (95% CI) | 77.2% (74.6–79.8%) | 75.1% (72.3–77.9%) | 2.1% (−1.5 to 5.7%) | 0.254 |
| Length of stay (days) | Mean (95% CI) | 9.2 (8.7–9.7) | 10.6 (10.0–11.2) | −1.4 (−2.1 to −0.7) | < 0.001 |
| Total hospital-borne costs*** | Mean (95% CI) | $50,174 ($46,727–$53,621) | $60,526 ($56,348–$64,705) | −$10,352 (−$13,628 to −$7,077) | < 0.001 |
CI confidence interval; IDM incremental difference in means (CSWWD minus 2OPMT); RR risk ratio
*Adjusted effect estimates and p-values are based on multilevel mixed-effects generalized linear models accounting for hospital level-clustering and the nested patient-within-hospital nature of the study data
**Discharged to home versus skilled nursing facility or other non-home setting
***2020 US dollars